Sparfosic Acid

Sparfosic Acid

SCHEMBL3514530

O=C(O)CC(NC(=O)CP(=O)(O)O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA2 P00918 4/20 1.00
CA4 P22748 1/20 1.00
ENO1 P06733 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43
HPGD P15428 1/20 0.43
TSHR P16473 1/20 0.43
BLM P54132 1/20 0.43
KMT2A Q03164 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
FOLH1 Q04609 1/20 0.42
RECQL P46063 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CASP3 P42574 1/20 0.42
OTC P00480 1/20 0.40
CA1 P00915 2/20 0.40
MME P08473 2/20 0.39
ENPEP Q07075 2/20 0.38
GAA P10253 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pala SCHEMBL59449 1.00 CA2 (1.00) CA2CA4ENO1MEN1LMNA
Sparfosic Acid SCHEMBL31237824 0.98 CA2 (0.96) CA2CA4ENO1MEN1LMNA
Pala SCHEMBL11121904 0.98 CA2 (0.96) CA2CA4ENO1MEN1LMNA
Pala SCHEMBL31389020 0.98 CA2 (0.96) CA2CA4ENO1MEN1LMNA
Pala SCHEMBL859680 0.98 CA2 (0.96) CA2CA4ENO1MEN1LMNA
SCHEMBL7747522 0.85 CA2 (0.74) CA2CA4ENO1MEN1KMT2A
Pala SCHEMBL3514468 0.85 CA2 (0.72) CA2CA4FOLH1OTC
SCHEMBL3513056 0.84 CA2 (0.71) CA2CA4HPGDFOLH1GGH
SCHEMBL12990268 0.84 CA2 (0.71) CA2CA4HPGDFOLH1GGH
Sparfosic Acid SCHEMBL28558641 0.84 CA2 (0.72) CA2CA4ENO1MEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 333 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3441089-B1 TREATMENT METHODS USING ADENOVIRUS VASCULAR BIOGENICS LTD (IL) 2022-12-14 EP claimed
EP-2714936-B1 METHODS AND PRODUCTS FOR PRODUCING ENGINEERED MAMMALIAN CELL LINES WITH AMPLIFIED TRANSGENES PREC BIOSCIENCES INC (US) 2018-12-12 EP claimed
CN-108060164-A A kind of siRNA for inhibiting RbAp48 genes and its prepare application in antineoplastic chemotherapy medicine sensitizer 南方医科大学 2018-05-22 CN claimed
CN-102666536-B 7-naphthyridine derivatives and the purposes as kinase inhibitor thereof AETERNA ZENTARIS GMBH (DE) 2016-03-30 CN claimed
WO-2026106969-A1 NOVEL INHIBITORS OF INTERLEUKIN RECEPTOR- ASSOCIATED KINASE UNIVERSITY OF ROCHESTER (US) 2026-05-21 WO disclosed
US-12616678-B2 Methods to of aldehyde dehydrogenases for treatment of cancer THE PENN STATE RESEARCH FOUNDATION (PA) 2026-05-05 US disclosed
EP-4724485-A1 BACKPACKED-ANTIBODY CONSTRUCTS AND THEIR USES Universidad del País Vasco/Euskal Herriko Unibertsitatea (ES) 2026-04-15 EP disclosed
EP-3547831-B1 HUMANIZED MOUSE MODEL WITH IMPROVED HUMAN INNATE IMMUNE CELL DEVELOPMENT JACKSON LAB (US) 2026-04-01 EP disclosed
EP-4706682-A2 SMALL MOLECULE TRAIL GENE INDUCTION BY NORMAL AND TUMOR CELLS AS AN ANTICANCER THERAPY The Penn State Research Foundation (US) 2026-03-11 EP disclosed
EP-4706684-A2 COMPOSITIONS AND METHODS FOR INCREASING THE EFFICACY OF IMMUNOTHERAPIES AND VACCINES The Regents of The University of Michigan (US) 2026-03-11 EP disclosed
US-20260062398-A1 CANNABICHROMENE DERIVATIVES AND USE THEREOF REMEDY PROCESSORS LLC (US) 2026-03-05 US disclosed
US-20260061093-A1 LIPID ANALOGS, LIPOSOMES COMPRISING SAME AND USES THEREOF LIPOSPHERE LTD. (IL) 2026-03-05 US disclosed
US-4730068-A SPECIAL EFFECT ON BREAST CANCER ASTA-WERKE AKTIENGESELLSCHAFT (DE) 1988-03-08 US disclosed
US-4704464-A CHELATE COMPOUNDS ASTA-WERKE AKTIENGESELLSCHAFT CHEMISCHE FABRIK (DE) 1987-11-03 US disclosed
EP-0116955-B1 COMPLEXES OF (1,2-DIPHENYL-ETHYLENE DIAMINE) PLATINUM (II) Degussa Aktiengesellschaft (DE) 1987-05-20 EP disclosed
EP-0204989-A2 Use of penicillamine in the treatment of immune deficiency diseases ASTA Medica Aktiengesellschaft (DE) 1986-12-17 EP disclosed
EP-0193083-A1 Anti-tumoral(1-arylmethyl-ethylene diamine)-platinum(II)-complexes ASTA Pharma AG (DE) 1986-09-03 EP disclosed
EP-0193055-A1 Antitumorals(1,2-diphenyl-ethylene diamine)-platinum (II) complexes ASTA Pharma AG (DE) 1986-09-03 EP disclosed
US-4598091-A (1,2-diphenyl)-ethylenediamine)-platinum (II) complex compounds DEGUSSA AKTIENGESELLSCHAFT (DE) 1986-07-01 US disclosed
EP-0116955-A2 Complexes of (1,2-diphenyl-ethylene diamine) platinum (II) Degussa Aktiengesellschaft (DE) 1984-08-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260062398-A1 CANNABICHROMENE DERIVATIVES AND USE THEREOF CTNND1, CNR2, CNR1 CA2 3401/4885CA4 3248/4885ENO1 4851/4885
US-20260061093-A1 LIPID ANALOGS, LIPOSOMES COMPRISING SAME AND USES THEREOF PHOSPHO1, SGMS1, SGMS2 CA2 855/4885CA4 579/4885ENO1 2430/4885
US-12616678-B2 Methods to of aldehyde dehydrogenases for treatment of cancer ALDH1A1, ALDH3A1, ADH1C CA2 148/4885CA4 309/4885ENO1 1042/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.